Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion type Assertion NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_head.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion wasGeneratedBy ECO_0000203 NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_provenance.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion wasDerivedFrom befree-20140225 NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_provenance.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion SIO_000772 16292549 NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_provenance.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion evidence source_evidence_literature NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_provenance.
- NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_assertion description "[Low-dose demethylating agents such as 5-aza-2'-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP743201.RArSOY5qv0mt9nZhyt0f7p_-pQuMT25P0-Uh3qOPaWVnA130_provenance.